

DT05 Rec'd PCT/PTO 01 FEB 2005

PATENT APPLICATION ¹/₂

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q86020

Motonori MIYAKAWA, *et al.*

National Stage Application of
PCT/JP03/09815
-filed August 1, 2003

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filed: February 1, 2005

Examiner: Not Yet Assigned

For: NOVEL TETRAHYDROQUINOLINE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

EP 1 221 439 is the corresponding English language application to WO 01/27086, which is listed on the International Search Report. US 2003/0087926 is the corresponding English language application to WO 01/58875, which is listed on the International Search Report.

Information Disclosure Statement
National Stage Application of
PCT/JP03/09815
-filed August 1, 2003

Q86020


The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860


Susan J. Mack
Registration No. 30,951

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: February 1, 2005

Substitute for Form 1449 A & B/PTO				DT05 USPTO PCT/PTO 01 FEB 2005		
				National Stage Application of PCT/JP03/09815 -filed August 1, 2003		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number		Not Yet Assigned
				Confirmation Number		February 1, 2005
				Filing Date		Motonori MIYAKAWA
				First Named Inventor		Not Yet Assigned
				Art Unit		Not Yet Assigned
				Examiner Name		Q86020
Sheet	1	of	1	Attorney Docket Number		Q86020

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 2003/0087926	A1	05-08-2003	Gerlach, <i>et al.</i>

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			
		EP	1 221 439	A1	07-10-2002	Kaken Pharmaceutical Co., Ltd	
		WO	96/19458	A2	06-27-1996	Ligand Pharmaceuticals Ltd.	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.